Developeration secures investment of 7,3 MSEK
A total of 7,3MSEK of investment is secured as convertible loan through investment from both existing investors and 4 new angel/private investors. The capital will be used for for finalising the clinical investigation and preparation of market introduction in the US.
International patent application accepted in EU, India, and Australia.
The patent application on the basic concept of PexyEazy® have been accepted in Australia, India and EU. The patent is now valid in USA, Japan, Singapore, Russia, South Africa, Israel, China, Australia and India, and pending in Canada and Brazil.
PexyEazy® is exhibited at the American Society for Colon and Rectal Surgeons (ASCRS) conference in Baltimore.
PexyEazy® was in the spotlight at the ASCRS conference in Baltimore 1-4 of June under the slogan “Mucopexy made easy. This event is one of the largest surgical conferences in the US with around 3000 participants. The event was very successful and PexyEazy® received an overwhelmingly positive response from attendees.
First PexyEazy® procedure done without general anestesia
As part of the ongoing clinical investigation, the SCI-Pex study, was the first PexyEaxy® procedure done on an awake patient, without general anesthesia. The procedure was successful and the patient was discharged on his/hers own request after only 15 minutes postoperatively which was possible thanks to that the patient experienced minimal pain after the PexyEazy® […]
International patent application accepted in USA, Japan, China etc.
The patent application on the basic concept of PexyEazy® is accepted in USA, Japan, Singapore, Russia, South Africa, Israel and China. The international patent applications in Canada, Brazil, EU, India and Australia are still pending. The second international patent application is also filed in Canada, USA, Brazil, EU, South Africa, Russia, Israel, Singapore, China, India, […]
First PexyEazy® procedure on human
First PexyEazy® procedure on human, as the first patient participated in the SCI-Pex study, a safety and feasibility study on PexyEazy®. A total of 35 patients will be included in the SCI-Pex study at two sites in Sweden.
Developeration secures 3,17MSEK of investment
Additional investment of 3,17MSEK is secured from existing investors to finance the upcoming clinical investigtion, the SCI-Pex study.
EIC Seal of Excellence
Developeration AB was awarded “Seal of Excellence” by the European Commission as part of the application for Horizon EIC 2022 Accelerator grant. Our application was scored as a high-quality project proposal in a highly competitive evaluation process. We were invited for interviews this time, but unfortunately did we not get the grant.
Most Innovative Operation Research & Development Company – Sweden
Developeration AB was awarded by the Scandinavian Business Awards as the “Most Innovative Operation Research & Development Company – Sweden”. https://www.eubusinessnews.com/winners/developeration-ab/
Second investment round
ALMI Invest, STOAF, Rentability AB, Adiuvero AB and GAEU Venture AB invest I Developeration AB’s second investment round, in total 11,5 MSEK.